Scrutiny Urged For FDA Divisions With High Number Of Delayed Postmarketing Studies
Executive Summary
Postmarketing studies are more likely to be delayed in some Center for Drug Evaluation and Research review divisions than others, and one of FDA’s consultants wants the agency to find out why.